Rebecca Crean
Overview
Explore the profile of Rebecca Crean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Oct;
30(1):304.
PMID: 37845513
No abstract available.
2.
Tjeertes J, Bacino C, Bichell T, Bird L, Bustamante M, Crean R, et al.
J Neurodev Disord
. 2023 Jul;
15(1):22.
PMID: 37495977
Background: Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by the absence of a functional UBE3A gene, which causes developmental, behavioral, and medical challenges. While currently untreatable, comprehensive data...
3.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Apr;
29(6):1437-1447.
PMID: 37095250
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting...
4.
Selamoglu A, Langley C, Crean R, Savulich G, Cormack F, Sahakian B, et al.
J Psychopharmacol
. 2021 Oct;
35(11):1349-1355.
PMID: 34694178
Background And Aims: Cannabis is a commonly used recreational drug in young adults. The worldwide prevalence in 18- to 25-year-olds is approximately 35%. Significant differences in cognitive performance have been...
5.
Mason B, Crean R, Goodell V, Light J, Quello S, Shadan F, et al.
Neuropsychopharmacology
. 2012 Mar;
37(7):1689-98.
PMID: 22373942
There are no FDA-approved pharmacotherapies for cannabis dependence. Cannabis is the most widely used illicit drug in the world, and patients seeking treatment for primary cannabis dependence represent 25% of...
6.
Mason B, Crean R
Expert Rev Neurother
. 2007 Nov;
7(11):1465-77.
PMID: 17997696
Acamprosate has been commercially available in the USA since 2004 to treat alcohol dependence. Its safety and efficacy have been demonstrated in a number of clinical trials worldwide, which overall...